Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A computational solution to improve biomarker reproducibility during long-term projects.

Feng F, Thompson MP, Thomas BE, Duffy ER, Kim J, Kurosawa S, Tashjian JY, Wei Y, Andry C, Stearns-Kurosawa DJ.

PLoS One. 2019 Apr 17;14(4):e0209060. doi: 10.1371/journal.pone.0209060. eCollection 2019.

2.

Dextran Sulfate Sodium Colitis Facilitates Colonization with Shiga Toxin-Producing Escherichia coli: a Novel Murine Model for the Study of Shiga Toxicosis.

Hall G, Kurosawa S, Stearns-Kurosawa DJ.

Infect Immun. 2018 Oct 25;86(11). pii: e00530-18. doi: 10.1128/IAI.00530-18. Print 2018 Nov.

3.

Microfluidic detection of movements of Escherichia coli for rapid antibiotic susceptibility testing.

Kara V, Duan C, Gupta K, Kurosawa S, Stearns-Kurosawa DJ, Ekinci KL.

Lab Chip. 2018 Feb 27;18(5):743-753. doi: 10.1039/c7lc01019b.

4.

Shiga Toxin Therapeutics: Beyond Neutralization.

Hall G, Kurosawa S, Stearns-Kurosawa DJ.

Toxins (Basel). 2017 Sep 19;9(9). pii: E291. doi: 10.3390/toxins9090291. Review.

5.

Pro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular Patterns.

Mayer CL, Parello CS, Lee BC, Itagaki K, Kurosawa S, Stearns-Kurosawa DJ.

Front Immunol. 2015 Apr 7;6:155. doi: 10.3389/fimmu.2015.00155. eCollection 2015.

6.

Complement, thrombotic microangiopathy and disseminated intravascular coagulation.

Kurosawa S, Stearns-Kurosawa DJ.

J Intensive Care. 2014 Dec 31;2(1):65. doi: 10.1186/s40560-014-0061-4. eCollection 2014. Review.

7.

Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury.

Parello CS, Mayer CL, Lee BC, Motomochi A, Kurosawa S, Stearns-Kurosawa DJ.

Toxins (Basel). 2015 Jan 20;7(1):170-86. doi: 10.3390/toxins7010170.

8.

Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C, Remick DG.

Physiol Rev. 2013 Jul;93(3):1247-88. doi: 10.1152/physrev.00037.2012.

9.

Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.

Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S.

Blood. 2013 Aug 1;122(5):803-6. doi: 10.1182/blood-2013-03-490060. Epub 2013 Jun 3.

10.

Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.

Stearns-Kurosawa DJ, Oh SY, Cherla RP, Lee MS, Tesh VL, Papin J, Henderson J, Kurosawa S.

Am J Pathol. 2013 Apr;182(4):1227-38. doi: 10.1016/j.ajpath.2012.12.026. Epub 2013 Feb 10.

11.

Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.

Sursal T, Stearns-Kurosawa DJ, Itagaki K, Oh SY, Sun S, Kurosawa S, Hauser CJ.

Shock. 2013 Jan;39(1):55-62. doi: 10.1097/SHK.0b013e318276f4ca.

12.

Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.

Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ.

Toxins (Basel). 2012 Nov 8;4(11):1261-87. doi: 10.3390/toxins4111261. Review.

13.

Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax.

Ghosh CC, Mukherjee A, David S, Knaus UG, Stearns-Kurosawa DJ, Kurosawa S, Parikh SM.

Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10024-9. doi: 10.1073/pnas.1120755109. Epub 2012 Jun 4. Erratum in: Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18625.

14.

Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Stearns-Kurosawa DJ, Collins V, Freeman S, Debord D, Nishikawa K, Oh SY, Leibowitz CS, Kurosawa S.

Pediatr Nephrol. 2011 Nov;26(11):2031-9. doi: 10.1007/s00467-011-1913-y. Epub 2011 May 21.

15.

The pathogenesis of sepsis.

Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG.

Annu Rev Pathol. 2011;6:19-48. doi: 10.1146/annurev-pathol-011110-130327. Review.

16.

Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli.

Stearns-Kurosawa DJ, Collins V, Freeman S, Tesh VL, Kurosawa S.

Infect Immun. 2010 Jun;78(6):2497-504. doi: 10.1128/IAI.01435-09. Epub 2010 Mar 22.

17.

PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study.

Reiner AP, Carty CL, Jenny NS, Nievergelt C, Cushman M, Stearns-Kurosawa DJ, Kurosawa S, Kuller LH, Lange LA.

J Thromb Haemost. 2008 Oct;6(10):1625-32. doi: 10.1111/j.1538-7836.2008.03118.x. Epub 2008 Aug 1.

18.

Soluble thrombomodulin: a sign of bad times.

Kurosawa S, Stearns-Kurosawa DJ, Kinasewitz GT.

Crit Care Med. 2008 Mar;36(3):985-7. doi: 10.1097/CCM.0B013E318165FDA7. No abstract available.

PMID:
18431290
19.

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.

Gynecol Oncol. 2007 Sep;106(3):596-603. Epub 2007 Jun 27.

PMID:
17597196
20.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD; Gynecologic Oncology Group.

Gynecol Oncol. 2007 May;105(2):508-16. Epub 2007 Feb 15.

21.

Proteinase 3 expression on neutrophil membranes from patients with infectious disease.

Matsumoto T, Kaneko T, Wada H, Kobayashi T, Abe Y, Nobori T, Shiku H, Stearns-Kurosawa DJ, Kurosawa S.

Shock. 2006 Aug;26(2):128-33.

PMID:
16878019
22.

Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S.

Am J Pathol. 2006 Aug;169(2):433-44.

23.

EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.

Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S.

Atherosclerosis. 2005 Dec;183(2):283-92.

PMID:
15921688
24.

Bimodal distribution of soluble endothelial protein C receptor levels in healthy populations.

Stearns-Kurosawa DJ, Burgin C, Parker D, Comp P, Kurosawa S.

J Thromb Haemost. 2003 Apr;1(4):855-6. No abstract available.

25.

Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide.

Kaneko T, Stearns-Kurosawa DJ, Taylor F Jr, Twigg M, Osaki K, Kinasewitz GT, Peer G, Kurosawa S.

Shock. 2003 Aug;20(2):130-7.

PMID:
12865656
26.

Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Boomsma MM, Stearns-Kurosawa DJ, Stegeman CA, Raschi E, Meroni PL, Kurosawa S, Tervaert JW.

Clin Exp Immunol. 2002 Apr;128(1):187-94.

27.

Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.

Stearns-Kurosawa DJ, Swindle K, D'Angelo A, Della Valle P, Fattorini A, Caron N, Grimaux M, Woodhams B, Kurosawa S.

Blood. 2002 Jan 15;99(2):526-30.

28.
29.

The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.

Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT.

Blood. 2000 Mar 1;95(5):1680-6.

30.

Endothelial protein C receptor.

Esmon CT, Xu J, Gu JM, Qu D, Laszik Z, Ferrell G, Stearns-Kurosawa DJ, Kurosawa S, Taylor FB Jr, Esmon NL.

Thromb Haemost. 1999 Aug;82(2):251-8. Review. No abstract available.

PMID:
10605711
31.

Regulation and functions of the protein C anticoagulant pathway.

Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, Kurosawa S.

Haematologica. 1999 Apr;84(4):363-8. Review.

32.

Inflammation, sepsis, and coagulation.

Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, Kurosawa S.

Haematologica. 1999 Mar;84(3):254-9. Review.

33.

A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity.

Smirnov MD, Safa O, Regan L, Mather T, Stearns-Kurosawa DJ, Kurosawa S, Rezaie AR, Esmon NL, Esmon CT.

J Biol Chem. 1998 Apr 10;273(15):9031-40.

34.
35.

Identification of functional endothelial protein C receptor in human plasma.

Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT.

J Clin Invest. 1997 Jul 15;100(2):411-8.

36.

The protein C pathway: new insights.

Esmon CT, Ding W, Yasuhiro K, Gu JM, Ferrell G, Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mather T, Laszik Z, Esmon NL.

Thromb Haemost. 1997 Jul;78(1):70-4. No abstract available.

PMID:
9198130
37.

The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.

Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10212-6.

38.

The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor.

Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT.

J Biol Chem. 1996 Jul 19;271(29):17491-8.

39.

The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors.

Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT.

J Biol Chem. 1996 Jul 19;271(29):17499-503.

40.

The effect of calcium ionophore A23187 on tissue factor activity and mRNA in endothelial cells.

Wakita K, Stearns-Kurosawa DJ, Marumoto Y.

Thromb Res. 1994 Apr 15;74(2):95-103.

PMID:
8029820

Supplemental Content

Loading ...
Support Center